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A b s t r a c t
Background: Acute hyperglycaemia in patients with myocardial infarction (MI) is an unfavourable predictive factor. However, 
there are limited data regarding the relationship between acute hyperglycaemia and the incidence of new onset diabetes in 
long-term observation. 
Aim: We studied the relationship between admission glycaemia in patients with MI and the future development of diabetes.
Methods: In 190 patients admitted during 2004–2007 with MI, diabetes was excluded on the basis of oral glucose tolerance 
test performed at the end of hospitalisation. Patients were divided into three groups according to admission glucose level: 
G1 < 7.8 mmol/L (< 140 mg/dL); G2: 7.8–11.0 mmol/L (140–199 mg/dL); and G3 ≥ 11.1 mmol/L (≥ 200 mg/dL). 
Results: The groups consisted of 80 (42.1%), 94 (49.5%), and 16 (8.4%) patients, respectively for G1, G2, and G3. The mean 
age was 61.3 ± 11.3 years. ST-segment elevation MI was diagnosed in 158 (83.2%) patients and non-ST-segment elevation 
MI in 32 (16.8%) patients. A total of 15 cases (7.9% of the study group) of newly diagnosed diabetes mellitus were registered 
during a mean follow-up of 48.2 ± 13.9 months. Higher incidence of new diabetes diagnosis was noticed in patients with 
higher glucose level on admission (5.0% vs. 7.4% vs. 25.0%, respectively; p = 0.0249). Regression analysis showed two inde-
pendent risk factors of diabetes development in the observational period: admission glucose level considered as a continuous 
variable with odds ratio (OR) 1.2 (95% CI 1.0–1.4, p = 0.03) and occurrence of impaired fasting glucose with OR 3.6 (95% 
CI 1.0–12.0, p = 0.04).
Conclusions: Patients with acute hyperglycaemia during MI are more likely to have diabetes in future. This group of patients 
requires close monitoring of glucose metabolism after MI.
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INTRODUCTION
Acute hyperglycaemia is a transient increase in blood glu-
cose level and reflects the response of the human body to 
stress such as myocardial infarction (MI) or stroke. Increased 
blood glucose level occurs regardless of previous diagnosis 
of diabetes and may be associated with normal glycated 
haemoglobin (HbA1C) values. In acute coronary syndrome 
(ACS) acute hyperglycaemia is found in all clinical types 
(ST-segment elevation MI [STEMI], non-ST-segment elevation 
MI [NSTEMI], and unstable angina) [1].
The mechanisms underlying the development of acute 
hyperglycaemia are still unclear. It might be the effect of 
a systemic reaction to stress (hypoxia, hypotension, local 
cardiomyocytes damage, pain, fear), which releases a process 
directed toward short-term optimisation of cardiovascular 
function [2]. Then it leads to hormonal changes causing blood 
glucose level increase [3]. Other possible causes of acute 
hyperglycaemia in the acute phase of MI could be previ-
ously undiagnosed glucose metabolism disorders. In normal 
conditions, insufficient insulin secretion by pancreatic beta 
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cells or hyperinsulinaemia, are subtle, compensated, and 
asymptomatic, but in severe stress reaction, when it is impos-
sible to compensate escalated hormonal changes, it leads to 
the development of hyperglycaemia. A similar mechanism 
of acute hyperglycaemia is found in patients with previously 
diagnosed diabetes mellitus where hormonal storm associ-
ated with cardiomyocyte damage during ischaemia leads to 
impairment of the endogenous mechanism to compensate 
for glucose level.  
Acute hyperglycaemia in patients with MI is an unfavour-
able predictive factor in short- and long-term observation 
[4–10]. However, there are limited data regarding the relation-
ship between acute hyperglycaemia in subjects with ACS and 
the incidence of new onset diabetes in long-term observation.
METHODS
Study population
The study involved patients without previously known dia-
betes, who were selected for an urgent invasive diagnosis of 
ischaemic heart disease and were hospitalised due to MI be-
tween 2004 and 2007 in the 1st Department of Cardiology and 
Hypertension of the University Hospital in Krakow. Initially, the 
study recruited 272 patients who agreed to participate. In all 
subjects admission glycaemia was measured. We evaluated de-
mographic data, angiographic parameters, echocardiographic 
changes, and selected laboratory measurements (maximum 
levels of troponin I and creatine kinase, lipidogram, glucose 
level on admission, creatine, and glomerular filtration rate). 
Patients were also assessed for the presence of the following 
risk factors: smoking status (a person who smoked until the 
hospitalisation and/or control visit was defined as a smoker), 
obesity (body mass index > 30 kg/m2), hypertension (systolic 
pressure ≥ 140 mm Hg and/or diastolic pressure ≥ 90 mm Hg 
or diagnosed previously), and hypercholesterolaemia (total 
cholesterol level ≥ 4.5 mg/dL or low density lipoprotein 
cholesterol > 2.5 mg/dL). Left ventricular ejection fraction 
(LVEF) was assessed using Simpson’s or Teichholz’s method 
during echocardiography (HP Sonos 5500). The STEMI was 
defined as the presence of symptoms of ischaemia, persistent 
ST segment elevation at least in two contiguous leads, or new 
left bundle branch block in electrocardiogram (ECG) with 
concomitant rise of cardiac biomarkers [11]. NSTEMI was 
defined as the presence of symptoms of ischaemia, rise of 
cardiac biomarkers, without new ST segment elevation, in at 
least two contiguous leads in ECG [12].
The metabolic syndrome was defined according to 
the United States National Cholesterol Education Program 
Adult Treatment Panel III (2001) as the presence of at least 
three of the following: central obesity: waist circumfer-
ence ≥ 102 cm (male), ≥ 88 cm (female); dyslipidaemia: tri-
glycerides ≥ 1.7 mmol/L (150 mg/dL); high density lipoprotein 
cholesterol < 40 mg/dL (male), < 50 mg/dL (female); blood 
pressure ≥ 130/85 mm Hg (or treated hypertension); or fasting 
plasma glucose ≥ 100 mg/dL (5.6 mmol/L) [13]. 
Diabetes diagnosis
During hospitalisation diabetes diagnosis was made accord-
ing to guidelines for diabetes diagnosis of the European 
Association for the Study of Diabetes (EASD) and Polish 
Diabetes Association (PDA), i.e. fasting plasma glucose in 
two consecutive days at least 126 mg/dL (7.0 mmol/L) or 
symptoms such as increased thirst, polyuria, weakness, and 
accidental glycaemia at least 200 mg/dL (11.1 mmol/L), or 
glucose level within 120 min after 75-g oral glucose load at 
least 200 mg/dL (11.1 mmol/L). Impaired fasting glucose (IFG) 
was diagnosed if the concentration of fasting glucose was in 
the range of 100–125 mg/dL (5.6–6.9 mmol/L). Diagnosis of 
impaired glucose tolerance (IGT) was made if within 120 min 
of oral glucose tolerance test (OGTT) the glucose level was 
140–199 mg/dL (7.8–11.1 mmol/L) [14, 15].
To exclude undiagnosed diabetes all patients underwent 
OGTT after acute phase of ACS (fourth day of hospitalisation 
or later). During hospitalisation 13 patients died, and diabetes 
was diagnosed in 69 patients — this group was excluded from 
further observation. Finally, 190 patients were enrolled into 
the study, with mean age 61.3 ± 11.3 years; 152 (80.0%) 
were men. STEMI was diagnosed in 158 (83.2%) subjects, 
and in 32 (16.8%) patients NSTEMI was found. Participants 
were categorised on the basis of admission glycaemia 
into three groups: G1 (admission glycaemia < 140 mg/dL 
[< 7.8 mmol/L]); G2 (admission glycaemia 140–199 mg/dL 
[7.8–11.0 mmol/L]); and G3 (admission glycaemia ≥ 200 mg/dL 
[≥ 11.1 mmol/L]). For one of the analyses, the study popula-
tion was divided into four groups according to glucose level 
on admission (Q1: < 111 mg/dL; Q2: 111–127 mg/dL; 
Q3: 128–152 mg/dL; Q4: ≥ 153 mg/dL).
The incidence of risk factors in the study group is pre-
sented in Table 1. The mean glucose level on admission 
was 7.8 ± 2.6 mmol/L, and the mean first fasting plasma 
glucose level was 5.6 ± 1.0 mmol/L. Group G1 consisted of 
80 (42.1%), G2 of 94 (49.5%), and G3 of 16 (8.4%) patients. 
Table 1. Incidence of risk factors in study group
Obesity 29 (15.3%)
Hypertension 132 (69.5%)
Dyslipidaemia 97 (51.1%)
Smokers 103 (54.2%)
Previous myocardial infarction 66 (34.7%)
Impaired fasting glucose 15 (7.9%)
Impaired glucose tolerance 62 (32.6%)
Metabolic syndrome 120 (63.2%)
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During the observational period (the mean follow-up was 
48.3 ± 13.9 months) occurrence of diabetes was assessed 
during ambulatory visit (based on interview, available medi-
cal documentation, or OGTT performed in persons without 
previously post-discharge diagnosis of diabetes) or on the 
basis of information received from family (for patients who 
died after hospital discharge). We did not diagnose diabetes 
on the basis of HbA1C value because this parameter was not 
considered by PDA or EASD as a diagnostic tool. 
This study complies with the Declaration of Helsinki and 
was approved by the Ethics Committee of Jagiellonian Univer-
sity. Informed consent was obtained from each patient. Source 
of founding — Collegium Medicum UJ statutory research grant.
Statistical analysis
Descriptive statistics were measured in order to summarise 
the collected data. The continuous variables were reported 
as median and interquartile or as means and standard devia-
tions. The categorical variables were reported as numbers 
and percentages. To determine if variables had normal 
distribution the Shapiro-Wilk test was implemented, and 
Levene’s test was used to assess the equality of variance in 
samples. Normally-distributed continuous variables were 
compared using Student’s t-test for dependent or independent 
samples as appropriate. The non-parametric Mann-Whitney 
U test or the Wilcoxon signed-rank test were used to com-
pare non-normally distributed variables. Pearson’s c2 test was 
applied to the categorical variables. Logistic regression was 
used to assess the factors that can have an influence on the 
end-point. For significant factors odds ratio (OR) and 95% 
confidence interval (CI) were measured. To assess the relation 
between continuous variables Pearson’s correlation coefficient 
(r) was applied. A p value < 0.05 was considered statistically 
significant. Statistical analysis was performed using Statistica 
PL software version 8.0.
RESULTS 
After discharge 42 (22.1%) participants of the study died 
(information about metabolic status was received from fam-
ily members).
The mean glucose level on admission in the groups G1, G2, 
and G3 is presented in Table 2. Patients with higher admission 
glucose level were older, more frequently had STEMI, metabolic 
syndrome, and IGT, and also had lower LVEF. In subjects with 
higher admission glucose the maximal levels of troponin I were 
higher, as well as maximal values of creatine phosphokinase; 
a trend towards higher maximal values of creatine kinase-MB 
was also observed. The highest level of first fasting glycaemia 
was observed in group G3. There were no significant differences 
in body mass index, estimated glomerular filtration rate, white 
blood cell count, cardiovascular risk factors, or IFG incidence 
between the mentioned groups (Table 2).
After follow-up (mean 48.2 ± 13.9 months) 15 new 
cases of diabetes were diagnosed (7.9% of the whole group). 
Occurrence of diabetes during the observational time was 
more frequently found in patients with higher glucose level 
on admission (Fig. 1). In the group with newly diagnosed 
diabetes the mean glucose level on admission was also signifi-
cantly higher (9.4 ± 4.3 vs. 7.7 ± 2.3 mmol/L, p = 0.0125). 
IFG was diagnosed during ambulatory visit among 20 of 
127 patients, and IGT in 21 (16.5%). There were no proven 
significant differences in the occurrence of IFG and IGT be-
tween groups G1, G2, and G3. There was only a tendency 
towards a higher percentage of IFG in G3 compared to the 
other groups (Table 3).
Among 77 patients with diagnosed IFG or IGT during 
hospitalisation, diabetes occurred in nine (11.7%), IGT in 
13 (16.9%), and IFG in three (3.9%) patients during follow-up.
Among groups Q1–Q4, a tendency towards a higher 
proportion of newly diagnosed diabetes in long-term observa-
tion was seen in groups with higher glycaemia on admission 
(Q1: 4.6%; Q2: 4.8%; Q3: 7.4%; and Q4: 13.2%, respec-
tively). However, there was no statistically significant differ-
ence between groups.
The results of logistic regression model prove two inde-
pendent risk factors for diabetes development in long-term 
follow up: glucose level on admission (considered as continu-
ous variable) with OR 1.2 (95% CI 1.0–1.4, p = 0.03) and 
occurrence of IGT with OR 3.6 (95% CI 1.0–12.0, p = 0.04). 
Other elements in this model of logistic regression were not 
proven as risk factors of diabetes development in long-term 
observation (Fig. 2).
DISCUSSION
Despite a number of publications concerning acute hypergly-
caemia, a precise and widely acceptable biochemical defini-
tion of acute hyperglycaemia has not been established yet. 
In studies evaluating the impact of acute hyperglycaemia the 
threshold level of hyperglycaemia has varied between 120 and 
200 mg/dL (6.7–11.1 mmol/L) for glycaemia on admission, 
and between 110 and 144 mg/dL (6.1–8.0 mmol/L) for the 
first fasting glucose level [2]. There is also no clear position 
of scientific societies in this area. The guidelines of PDA 
define “relative hyperglycaemia” as glycaemia > 140 mg/dL 
(7.8 mmol/L) in patients without previously diagnosed diabetes 
and > 180 mg/dL (10.0 mmol/L) in diabetics [14]. American 
guidelines published in 2011 recommend that hyperglycae-
mia ≥ 180 mg/dL (10.0 mmol/L) in diabetics requires hypo-
glycaemic treatment [16]. The threshold of hyperglycaemia 
in non-diabetics was not clearly specified in these guidelines 
[16].  Our study population was divided into three groups, and 
glucose levels on admission of 140 mg/dL (7.8 mmol/L) and 
200 mg/dL (11.1 mmol/L) were taken as cut-off points. Such 
a division has also been used by other investigators [2, 8, 9].
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There are limited data regarding the relation between 
acute hyperglycaemia in patients with ACS and the frequency 
of new onset of diabetes in long-term observation. In our 
study, based on an unselected, consecutive cohort of patients 
with MI, in which diabetes was excluded on the basis of OGTT 
performed during the index hospitalisation, newly diagnosed 
diabetes during a four-year follow-up period occurred more 
often in patients with acute hyperglycaemia. On the basis of 
logistic regression it was proven that admission glucose level 
and diagnosis of IGT during hospitalisation are independent 
risk factors of diabetes development in long-term observa-
tion. To our knowledge, so far there has only been one study 
published assessing the relation between hyperglycaemia in 
patients with ACS and the occurrence of new incidences of 
diabetes in long-term observation [17]: the KORA register 
database including 1293 non-diabetic patients with MI. 
The study population was divided into four groups accord-
ing to glucose level on admission (Q1: < 111 mg/dL; Q2: 
111–127 mg/dL; Q3: 128–152 mg/dL; and Q4: ≥ 153 mg/dL). 
The mean follow-up was 4.7 years, and during this period 
diabetes was diagnosed in 108 subjects. The authors presented 
strong correlation between admission glucose level and the 
frequency of newly diagnosed diabetes in long-term obser-
vation. Compared to acute MI patients with blood glucose 
level on admission of 111 mg/dL (group Q1), patients with 
levels ≥ 153 mg/mL (group Q4) had a 2.6-fold higher risk of 
diabetes [17]. When we also divided the study population 
into four groups in accordance with the cut-off point in the 
KORA registry, in groups with higher glycaemia diabetes was 
Table 2. In-hospital demographic, clinical, and laboratory data 
Group1 (n = 80) Group 2 (n = 94) Group 3 (n = 16) P
Age [years] 59.3 ± 11.5 63.9 ± 11.7 68.7 ± 13.1 0.0030 a, c
Women 13 (16.3%) 22 (23.4%) 3 (18.8%) 0.494
STEMI 60 (75.0%) 84 (89.4%) 14 (87.5%) 0.0369 a
NSTEMI 20 (25.0%) 10 (10.6%) 2 (12.5%) 0.0369 a
Body mass index [kg/m2] 25.9±3.3 27.0±3.8 27.3±2.7 0.124
Obesity 10 (12.5%) 17 (18.9%) 2 (12.5%) 0.563
Metabolic syndrome 44 (55.0%) 55 (58.5%) 16 (100.0%) 0.003 b, c
Smokers 46 (57.5%) 50 (53.2%) 7 (43.8%) 0.579
Hypertension 50 (62.5%) 71 (75.5%) 11 (68.8%) 0.177
Dyslipidaemia 44 (55.0%) 48 (51.6%) 5 (31.3%) 0.216
Previous myocardial infarction 11 (13.8%) 20 (21.3%) 3 (18.6%) 0.433
LVEF [%] 51.1 ± 7.7 50.6 ± 9.7 41.0 ± 12.4 0.0038 a, b
Troponin I max [ng/mL] 10.8 ± 13.1 14.2 ± 15.5 27.2 ± 17.9 0.0296 b
CPK max [U/L] 1670.3 ± 2185.2 2228.9 ± 2773.3 3970.7 ± 3864.1 0.0402 b
CK-MB max [U/L] 200.8 ± 261.8 237.8 ± 247.2 496.6 ± 490.9 0.051 
eGFR [mL/min/1.73 m2] 80.3 ± 24.8 73.1 ± 24.8 63.4 ± 24.7 0.228
WBC [thousand/mm3] 10.4 ± 3.3 10.7 ± 3.4 14.7 ± 4.4 0.199
Admission glucose level [mmol/L] 5.9 ± 0.7 8.9 ± 0.9 14.2 ± 3.0 < 0.0001a, b, c
First fasting glucose level [mmol/L] 5.3 ± 0.7 5.8 ± 1.0 6.3 ± 1.6 < 0.0001 b, c
Impaired fasting glucose 9 (11.2%) 6 (6.4%) 0 (0.0%) 0,131
Impaired glucose tolerance 20 (25.0%) 33 (35.1%) 9 (56.2%) 0.0399 c
ap < 0.05 for Group 1 vs. Group 2; bp < 0.05 for Group 2 vs. Group 3; cp < 0.05 for Group 1 vs. Group 3; CK-MB — isoenzyme of creatine kinase 
with muscle and brain subunits; CPK — creatine phosphokinase; eGFR — estimated glomerular filtration rate; LVEF — left ventricular ejection fraction; 
NSTEMI — non-ST-segment elevation myocardial infarction; STEMI — ST-segment elevation myocardial infarction; WBC — white blood cell count
Figure 1. New incidences of diabetes in long-term obser-
vation; ap < 0.05 for Group 2 vs. Group 3; bp < 0.05 for 
Group 1 vs. Group 3
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diagnosed more often in long-term observation. However, 
there was only a statistically non-significant tendency.
The results of our study and the KORA registry suggest 
that acute hyperglycaemia in patients with ACS could be an 
early marker of glucose homeostasis disturbances, which after 
a longer period may reach the diabetes criteria. Impaired 
glucose metabolism — asymptomatic and entirely compen-
sated in stable condition — in the early phase of MI, during 
severe stress reaction when compensation is impossible, may 
elicit hyperglycaemia, but after the acute phase and relative 
stabilisation phase may subside and not allow diagnosis of 
impaired glucose metabolism in the peri-infarction period. 
However, in a longer observation period, due to increasing 
insulin resistance and progressive decrease in insulin excre-
tion, these patients could have a higher probability of diabetes 
development. 
It is important to underline that, in our study, patients 
with higher glucose level on admission had more frequent 
metabolic syndrome and IGT in hospital. A tendency towards 
higher proportion of patients with IFG was also observed in 
this group.
Recommendations for long-term management of patients 
with hyperglycaemia in the acute phase of ACS are not yet 
specified. Nevertheless, data indicating the relation between 
higher admission glucose level and increased incidence of 
diabetes in subjects with ACS have important clinical im-
plications. Particularly in this group, non-pharmacological 
interventions, such as regular physical activity, proper diet, 
and loss of weight should be strictly implemented because 
they are of great importance in the reduction of progression 
and treatment of impaired glucose metabolism. 
Although the guidelines do not separately mention sub-
jects with acute hyperglycaemia, it is recommended that in 
patients with higher risk, including those with cardiovascular 
diseases, diabetes screening tests should be repeated [14–16]. 
These tests have particular significance in patients with acute 
hyperglycaemia during MI as they enable early diagnosis of 
impaired glucose metabolism and implementation of optimal 
treatment. 
Limitations of the study
The present study has several limitations that need to be con-
sidered. The number of patients studied (especially patients 
with NSTEMI) is limited. Due to the observational nature of 
this study, the possibility of selection bias and/or residual con-
founding from unknown or unmeasured covariates cannot be 
excluded. Our study is a single-centre observational study, so 
we should be cautious about hypothesising the mechanisms 
involved and the generalisability of our conclusions to other 
populations. According to guidelines, it is recommended to 
use a specific screening tool in patients with cardiovascular 
risk factors to assess the risk of diabetes development in the 
future. Due to the partially retrospective character of our study 
and the lack of some data (dietary habits, physical activity, 
family history, etc.), we did not use any risk score for the risk 
of diabetes development. Diabetes diagnosis at follow-up in 
our study depended on the basis of OGTT performed during 
ambulatory visit or information received from the family (for 
Table 3. Follow-up incidence of pre-diabetic states 
Group 1 (n = 55) Group 2 (n = 61) Group 3 (n = 11) P
Impaired fasting glucose (IFG) 5 (9.1%) 12 (19.7%) 3 (27.3%) 0.156
Impaired glucose tolerance (IGT) 9 (16.4%) 11 (18.0%) 1 (9.1%) 0.737
IFG or IGT 14 (25.4%) 23 (37.7%) 4 (36.4%) 0.349
Figure 2. Risk factors of diabetes development in long-term observation. To summarise the results of logistic regression odds 
ratio (squares), 95% confidence interval (lines) and statistical significance (p) are presented (forest plot)
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patients who died after hospital discharge) that could have 
affected the findings. We did not diagnose diabetes on the 
basis of HbA1C values as this parameter was not considered 
by the PDA as a diagnostic tool. 
CONCLUSIONS
Patients with higher glucose level during acute phase of MI 
have higher risk of diabetes incidence in the future. In subjects 
suffering from MI the strict screening of glucose disturbance 
should be applied.
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Ryzyko rozwoju cukrzycy w obserwacji odległej 
u pacjentów z zawałem serca i hiperglikemią  
ostrej fazy
Michał Terlecki, Leszek Bryniarski, Agnieszka Bednarek, Maryla Kocowska, Kalina Kawecka-Jaszcz,  
Danuta Czarnecka
I Klinika Kardiologii i Elektrokardiologii Interwencyjnej oraz Nadciśnienia Tętniczego, Uniwersytet Jagielloński, Collegium Medicum, Kraków
S t r e s z c z e n i e
Wstęp: Ostrej reakcji stresowej, którą dla organizmu może być zawał serca (MI) lub udar mózgu, towarzyszy przejściowy 
wzrost stężenia glukozy we krwi. Z dotychczas opublikowanych badań wynika, że u pacjentów z MI hiperglikemia ostrej fazy 
jest niekorzystnym czynnikiem rokowniczym zarówno w obserwacji krótko-, jak i długoterminowej. Brakuje jednak danych 
oceniających związek między hiperglikemią ostrej fazy u chorych z MI a częstością występowania nowych przypadków 
cukrzycy w obserwacji odległej.
Cel: Celem badania była ocena związku między stężeniem glukozy podczas ostrej fazy MI a częstością występowania nowych 
przypadków cukrzycy w obserwacji odległej.
Metody: Do badania włączono 272 pacjentów hospitalizowanych w latach 2004–2007 w I Klinice Kardiologii i Nadciśnienia 
Tętniczego Szpitala Uniwersyteckiego w Krakowie z powodu MI, bez uprzednio rozpoznanej cukrzycy. Każdemu uczestni-
kowi badania oznaczono stężenie glukozy we krwi przy przyjęciu i wykonano test obciążenia glukozą (OGTT). Wykluczono 
pacjentów, którzy zmarli w czasie hospitalizacji oraz chorych, u których na podstawie wykonanego pod koniec hospitalizacji 
OGTT rozpoznano cukrzycę, opierając się na wytycznych Polskiego Towarzystwa Diabetologicznego. Ostatecznie do badania 
włączono 190 osób. Chorych podzielono na grupy w zależności od stężenia glukozy przy przyjęciu (G1: stężenie glukozy przy 
przyjęciu < 7,8 mmol/l, tj. < 140 mg/dl; G2: stężenie glukozy przy przyjęciu: 7,8–11,0 mmol/l, tj. 140–199 mg/dl; G3: stężenie 
glukozy przy przyjęciu ≥ 11,1 mmol/l, tj. ≥ 200 mg/dl). Po okresie obserwacji (48,3 ± 13,9 miesiąca) poszukiwano nowych 
przypadków cukrzycy u uczestników badania, wykonując OGTT (o ile nie rozpoznano cukrzycy przed wizytą kontrolną). 
W przypadku osób, które zmarły w okresie obserwacji, uzyskiwano informację na temat rozpoznania cukrzycy od ich rodzin.
Wyniki: Liczebność grup G1, G2, G3 wyniosła odpowiednio 80 (42,1%), 94 (49,5%) i 16 (8,4%) pacjentów. Średni wiek uczest-
ników badania wynosił 61,3 ± 11,3 roku. U 158 (83,2%) chorych rozpoznano MI z uniesieniem załamka ST, a u 32 (16,8%) 
MI bez uniesienia załamka ST. Po okresie obserwacji wynoszącej 48,2 ± 13,9 miesiąca zanotowano 15 nowych przypadków 
cukrzycy (7,9% spośród całej obserwowanej grupy). Większą częstość nowych przypadków cukrzycy stwierdzono u chorych, 
którzy mieli wyższe stężenia glukozy przy przyjęciu (5,0% vs. 7,4% vs. 25,0%; p = 0,0249). W modelu regresji logistycznej 
wykazano dwa niezależne czynniki ryzyka rozwoju cukrzycy w obserwacji odległej: stężenie glukozy przy przyjęciu do szpitala 
oceniane jako zmienna ciągła (OR 1,2; 95% CI 1,0–1,4; p = 0,03) i nieprawidłowa tolerancja glukozy stwierdzona w czasie 
hospitalizacji (OR 3,6; 95% CI 1,0–12,0; p = 0,04).
Wnioski: Chorzy z wyższymi stężeniami glukozy w ostrej fazie MI są bardziej narażeni na ryzyko rozwoju cukrzycy w przyszło-
ści. Ścisłe monitorowanie zaburzeń gospodarki węglowodanowej po przebyciu MI u tych pacjentów jest szczególnie istotne.
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